Skip to Content

Curaleaf Holdings Inc CURA Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CURA

Currency in CAD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Curaleaf Remains Well Positioned to Benefit From Both U.S. and European Legal Market Growth

Business Strategy and Outlook

| Kristoffer Inton |

Curaleaf cultivates and sells cannabis in the U.S. with a presence in 22 states. Unlike the Canadian cannabis producers, Curaleaf is much more vertically integrated with 26 cultivation sites and 136 dispensaries. It gives investors full exposure to the U.S. cannabis market, the fastest growing and largest potential market. Compared with other multistate operators, Curaleaf employs a more aggressive growth strategy, entering states flush with competitors.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CURA

Company Profile CURA

Business Description

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 22 states, including the assets from the Cura Select and Grassroots acquisitions. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.

301 Edgewater Place #110, Suite 405
Wakefield, MA, 01880
T +1 781 451-0150
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 5,671